Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis

BACKGROUND: Warfarin is the standard of care and NOAC (Novel oral anticoagulants) are a group of newer drugs for such purposes. NOAC has a generally better profile (Clear interaction, less side effect, require less monitoring). However, its efficacy on valvular atrial fibrillation remains unclear. M...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qiyu, Sze, Chun-Yat, Shum, Tin-Yau, Hao, Guang, Wong, Nga-Yin Belinda, Sin, Tat-Hang, Wei, Wei, Xia, Sujian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521383/
https://www.ncbi.nlm.nih.gov/pubmed/31092194
http://dx.doi.org/10.1186/s12872-019-1089-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521383/
https://www.ncbi.nlm.nih.gov/pubmed/31092194
http://dx.doi.org/10.1186/s12872-019-1089-0

Ejemplares similares